On November 5, 2021 Race Oncology Limited ("Race") reported that congratulates Dr Joshua Brzozowski from the laboratory of Associate Professor Nikki Verrills, University of Newcastle, for winning the Best Poster Prize in the Biomarkers and Targeted Therapy section at the Hunter Cancer Research Symposium on November 4, 2021 (Press release, Race Oncology, NOV 5, 2021, View Source [SID1234594671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation entitled "Preclinical efficacy of bisantrene for the treatment of breast cancer" describes the use of Zantrene (bisantrene dihydrochloride) in breast cancer cells and identified two key highlights:

Drug-resistant breast cancer cells are more sensitive to treatment with Zantrene compared to other anthracyclines, such as doxorubicin or epirubicin.
Zantrene has additive or synergistic activity when used with cyclophosphamide (a widely used breast cancer drug) in human breast cancer cell lines.
This presentation expands on results previously reported from the Verrills Laboratory (ASX announcement: 9 March 2021).